Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

TODD A TAYLOR

Allopathic & Osteopathic Physicians Family Medicine

NPI
1619911765
CMS profile
209091
Location
MIFFLINTOWN, PA

General Payments · PY2018–2024

$4,154.68

  • Reported across 322 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$252.03

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $252.03 13

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $67.60 4
Astellas Pharma US Inc $54.38 2
ABBVIE INC. $33.05 1
Acerta Pharma LLC $31.79 2
DEXCOM, INC. $20.95 1
PFIZER INC. $16.51 1
Boehringer Ingelheim Pharmaceuticals, Inc. $14.39 1
Novo Nordisk AS $13.36 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,342.82 125
PY2019 $1,086.53 94
PY2020 $75.72 6
PY2021 $362.02 23
PY2022 $492.93 29
PY2023 $542.63 32
PY2024 $252.03 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $33.05 03/05/2024 Food and Beverage Undisputed 01/23/2026 1106207509 CMS
Astellas Pharma US Inc $30.38 02/23/2024 Food and Beverage Undisputed 01/23/2026 1139319160 CMS
Astellas Pharma US Inc $24.00 04/04/2024 Food and Beverage Undisputed 01/23/2026 1139305408 CMS
AstraZeneca Pharmaceuticals LP $16.31 01/24/2024 Food and Beverage Undisputed 01/23/2026 1104420185 CMS
AstraZeneca Pharmaceuticals LP $15.48 05/08/2024 Food and Beverage Undisputed 01/23/2026 1105894838 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.39 01/03/2024 Food and Beverage Undisputed 01/23/2026 1118083016 CMS
Dexcom, Inc. $20.95 07/17/2024 Food and Beverage Undisputed 01/23/2026 1153341439 CMS
GlaxoSmithKline, LLC. $17.57 02/08/2024 Food and Beverage Undisputed 01/23/2026 1116695267 CMS
GlaxoSmithKline, LLC. $18.84 08/14/2024 Food and Beverage Undisputed 01/23/2026 1115905335 CMS
GlaxoSmithKline, LLC. $14.94 11/06/2024 Food and Beverage Undisputed 01/23/2026 1116325292 CMS
GlaxoSmithKline, LLC. $16.25 11/21/2024 Food and Beverage Undisputed 01/23/2026 1116026482 CMS
Novo Nordisk Inc $13.36 01/11/2024 Food and Beverage Undisputed 01/23/2026 1097442748 CMS
PFIZER INC. $16.51 07/22/2024 Food and Beverage Undisputed 01/23/2026 1131739914 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.